Document:

caba-ex1029_58.htm

 

Exhibit 10.29

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

SPONSORED RESEARCH AGREEMENT

This Sponsored Research Agreement (“Agreement”) is dated as of December 23, 2021 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd, 9th Floor, Philadelphia, PA 19104-4310, and Cabaletta Bio, Inc., a Delaware corporation (“Sponsor”), having a place of business at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.  Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.

RECITALS:

WHEREAS, Penn and Sponsor are entering into this Agreement since Sponsor desires to fund the research of Drew Weissman, MD, PhD of Penn’s Perelman School of Medicine in certain specific areas;

WHEREAS, Sponsor desires to support such research conducted by Penn in accordance with the terms and conditions of this Agreement;

WHEREAS, the research program contemplated by this Agreement is of mutual interest to Sponsor and Penn and furthers the educational, scholarship and research objectives of Penn as a nonprofit, tax-exempt, educational institution, and may benefit both Sponsor and Penn through the creation or discovery of new inventions;

WHEREAS, the Parties, have entered into a license agreement and sponsored research agreements for the development and commercialization of chimeric autoantibody receptor (CAAR) T cells; and

WHEREAS, the Parties have entered into an option agreement concurrently with this Agreement for certain patent rights related to targeted mRNA-LNP technology invented by Drew Weissman MD, PhD and others at Penn.

NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows:

Article 1
DEFINITIONS

	
1.1
	
“Antigen Group I” means [***].

	
1.2
	
“Antigen Group II” means [***].

	
1.3
	
“Background IP Option Agreement” means the option agreement between the Parties with the same Effective Date as the Agreement related to targeted mRNA-LNP technology invented in the Weissman laboratory at Penn.

1

 

	
1.4
	
“mRNA Chimeric Autoantibody Receptor Product” or “mRNA CAAR Product” means [***].

	
1.5
	
“Chimeric Autoantibody Receptor T Cell Product” or “CAAR T Product” means [***].

	
1.6
	
“mRNA Chimeric Autoantibody Receptor T Cell Product” or “mRNA CAAR T Product” is a [***].

	
1.7
	
“CAAR-Potentiating mRNA Vaccine Product” means [***].

	
1.8
	
“Field of Use” means the following subfields (each a “Subfield”):  [***].

	
1.9
	
“License Agreement” means the Cabaletta Amended and Restated License Agreement (CARLA) effective July 23, 2019 by and among Penn, CHOP, and Cabaletta Bio, as amended by its First Amendment dated May 1, 2020 and its Second Amendment dated October 19, 2021.

	
1.10
	
“mRNA-Enabled CAAR Products” means [***].

	
1.11
	
“Penn Intellectual Property” means Related Intellectual Property and Unrelated Intellectual Property, each as defined below.

	
1.12
	
“Principal Investigator” means Drew Weissman, MD, PhD who has agreed to serve as faculty investigator for the Sponsored Research and shall be responsible for the conduct, supervision and administration of the Sponsored Research.

	
1.13
	
“Related Intellectual Property” means all inventions, whether patentable or not, that are (a) conceived (as determined by United States patent law) in the conduct of the Sponsored Research during the Term, and (b) during the Term either (i) reduced to practice (as determined by United States patent law) in the conduct of the Sponsored Research, or (ii) disclosed to Penn’s Penn Center for Innovation on an invention disclosure form, and (c) that are related to or have applicability in connection with the development and research of [***], including, in each case, all United States and foreign patent applications claiming said patentable inventions, including any divisional, continuation, continuation-in-part (to the extent that the claims are directed to said patentable inventions), and foreign equivalents thereof, as well as any patents issued thereon or reissues or reexaminations thereof.  For clarity, Related Intellectual Property also includes all significant copyrights and copyrightable software created in the conduct of the Sponsored Research during the term of this Agreement and that have applicability in connection with the development and research of [***].

	
1.14
	
“Penn mRNA Information” means any know-how, materials, technical information, data, methods and other information that is (a) necessary or useful for the research, development, manufacturing, commercialization, application, use or practice, as applicable, of Penn Intellectual Property or any [***], (b) not any construct directed against CD 19, (c) emergent from performance of the Sponsored Research in the laboratory of Dr. Drew Weissman, (d) controlled by Penn, and (e) identified and clearly documented in a discrete written form.

	
1.15
	
“Research Results” means all data and information which are generated in the performance of the Sponsored Research during the term of this Agreement.  Research Results expressly excludes Penn Intellectual Property.

	
1.16
	
“Sponsored Research” means the research program described in Attachment A to this Agreement.

2

 

		

	
1.17
	
“Unrelated Intellectual Property” means all inventions, whether patentable or not, that are (a) conceived (as determined by United States patent law) in the conduct of the Sponsored Research during the Term, and (b) during the Term either (i) reduced to practice (as determined by United States patent law) in the conduct of the Sponsored Research or (ii) disclosed to Penn’s Penn Center for Innovation on an invention disclosure form, and that are not a) Related Intellectual Property or b) an invention directed against CD 19, including all United States and foreign patent applications claiming said patentable inventions, including any divisional, continuation, continuation-in-part (to the extent that the claims are directed to said patentable inventions), and foreign equivalents thereof, as well as any patents issued thereon or reissues or reexaminations thereof.

	
1.18
	
Other Terms.  The definition of each of the following terms is set forth in the section of the Agreement indicated below.

		
	
Defined Term
	
Section

	
Agreement
	
Preamble

	
Confidential Information
	
6.1

	
Effective Date
	
Preamble

	
First Refusal Period
	
5.6.3

	
Future CAAR Target
	
5.6.3

	
Option Exercise Notice
	
5.6.1

	
Option Period
	
5.6.1

	
Negotiation Period
	
5.6.1

	
Party or Parties
	
Preamble

	
Penn
	
Preamble

	
Penn Indemnitees
	
8.2

	
Sponsor
	
Preamble

 

Article 2
SPONSORED RESEARCH

	
2.1
	
Conduct.  Penn shall commence the Sponsored Research after the Effective Date of this Agreement and upon payment by Sponsor of any funds owed, and shall conduct such Sponsored Research in accordance with the terms and conditions of this Agreement.  Sponsor acknowledges that Penn and the Principal Investigator shall have the freedom to conduct and supervise the Sponsored Research in a manner consistent with Penn’s educational and research missions.

	
2.2
	
Principal Investigator.  If the services of the Principal Investigator become unavailable to Penn for any reason, Penn shall be entitled to designate another member of its faculty who is acceptable to Sponsor to serve as the Principal Investigator of the Sponsored Research.  If a substitute Principal Investigator has not been designated within [***] after the original Principal Investigator ceases his or her services under this Agreement, either Party may terminate this Agreement upon written notice thereof to the other Party, subject to the provisions of ARTICLE 7.

Article 3
REIMBURSEMENT OF COSTS & PAYMENT

	
3.1
	
Reimbursement.  Sponsor shall reimburse Penn for an amount equal to its expenditures and reasonable overhead incurred in the conduct of the Sponsored Research in an amount not to exceed the total amount of [***] as set forth in Attachment A.  Sponsor acknowledges that this amount is a good faith estimate only and not a guarantee of the cost to conduct the Sponsored Research.  If at 

3

 

		
any time Penn determines that it will require additional funds for the Sponsored Research, it shall notify Sponsor and provide an estimate of the additional amount.  Sponsor shall not be liable for any costs in excess of the amount of [***] unless it has agreed in writing to provide additional funds.  All amounts provided by Sponsor shall be used only for the Sponsored Research.

	
3.2
	
Payment.  Sponsor shall make payments in advance to Penn in accordance with the payment schedule set forth in Attachment A.  All payments shall clearly identify the Principal Investigator, Penn ERA Number [***], and the term “sponsored research”.  All payments are to be payable in United States dollars, and if by check, made out to “The Trustees of the University of Pennsylvania”, and sent to:

[***]For all payments made by wire transfer (preferred for sponsored research agreements), banking information is as follows:

Banking Information:

	
Bank Name:
	
[***]

	
Bank Address:
	
[***]

	
ACH Coordinator:
	
[***]

	
Account Title:
	
[***]

	
Account Type:
	
[***]

	
Account #:
	
[***]

	
ABA Routing #:
	
[***]

	
SWIFT CODE:
	
[***]

	
CHIPS:
	
[***]

	
Reference:
	
[***]

 

	
3.3
	
Equipment.  Title to any equipment, laboratory animals, or any other materials made or acquired with funds provided under this Agreement shall vest in Penn, and such equipment, animals, or materials shall remain the property of Penn following termination of this Agreement.

Article 4
RESEARCH RESULTS; RECORDS AND REPORTS

	
4.1
	
Research Results.  Sponsor shall have the right to use Research Results disclosed to Sponsor in records and reports for any lawful purpose subject to the limitations in Section 6.3.  Sponsor shall need to obtain a license to use Research Results from Penn if such use would infringe any copyright or any claim of a patent application or issued patent owned by Penn, except to the extent such license is granted pursuant to this Agreement or any other agreement between the Parties.

	
4.2
	
Records.  Principal Investigator shall maintain records of the results of the Sponsored Research and shall provide Sponsor with reports of the progress and results of the Sponsored Research in accordance with Attachment A.  Penn shall maintain records of the use of the funds provided by Sponsor and no later than [***] following the end of each calendar quarter, shall provide to Sponsor a summary report of the use of such funds during such calendar quarter.

	
4.3
	
Research Reports.  Penn hereby grants Sponsor a royalty-free, nontransferable, non-exclusive right to copy, reproduce and distribute any research reports furnished to Sponsor under this Agreement, or any excerpts or portions thereof, subject to the limitations in Section 6.3.  Sponsor may not charge fees for said research reports, use said research reports for advertising or 

4

 

		
promotional activities, or alter or modify said research reports (other than creating excerpts or portions thereof) without the prior written permission of Penn.

Article 5
INTELLECTUAL PROPERTY

	
5.1
	
Penn Intellectual Property.  Penn shall retain all right, title and interest in and to Penn Intellectual Property and any patents, copyrights, software and tangible research materials and other intellectual property related thereto.

	
5.2
	
Disclosure.  Principal Investigator shall provide Penn and Sponsor a written disclosure of any Penn Intellectual Property reasonably considered patentable.  After Sponsor has confirmed receipt of such disclosure (which confirmation can be by email and shall be delivered within [***] of Sponsor’s receipt of such disclosure), Sponsor shall advise Penn in writing, no later than [***] after such confirmation of receipt of such disclosure, whether it requests Penn to file and prosecute patent applications related to such Penn Intellectual Property.  If Sponsor does not request Penn to file and prosecute such patent applications, Penn may proceed with such preparation and prosecution at its own cost and expense, provided that Penn will first notify Sponsor of its intent to do so.  Sponsor shall have [***] from Sponsor’s confirmed receipt of such notification to notify Penn that it is electing to retain its rights to such Penn Intellectual Property under Section 5.6, and if Sponsor provides such notification, the terms of Section 5.3 shall apply, including Sponsor’s obligation to pay patent expenses, as if Sponsor had requested that Penn file and prosecute such patent applications.  If Sponsor fails to so notify Penn of such election, then Penn may proceed with such preparation and prosecution at its own cost and expense, and such patent applications shall be excluded from Sponsor’s option under Section 6 hereof, provided, however, that upon Sponsor’s request, Penn shall update Sponsor on the filing status of any patent applications related to such Penn Intellectual Property.

	
5.3
	
Prosecution.  Except as may otherwise be agreed by the Parties, Penn shall control the preparation and prosecution of all patent applications and the maintenance of all patents related to Penn Intellectual Property.  With regard to any patent applications filed at the request and expense of Sponsor, Penn will, through its patent counsel, consult with Sponsor on patent prosecution.  The Parties intend that the common interest privilege will apply to such consultation, but in no event shall such consultation be construed to imply that either Party’s counsel represents the other Party in connection with such patent filings and/or prosecution.  Sponsor shall reimburse Penn within [***] after receipt of invoice for all documented out-of-pocket patent and legal expenses incurred by Penn in connection with the filing and prosecution of the patent applications and maintenance of the patents that Sponsor has requested Penn to prosecute under Section 5.2 hereof, according to the following schedule:  (a) for Related Intellectual Property subject to an exclusive option, the Sponsor shall reimburse all patent and legal expenses; (b) for Unrelated Intellectual Property subject to a non-exclusive option, the Sponsor shall reimburse pro-rata with other active commercial licensees or optionees, and [***] of the expenses if there do not exist any other active commercial licensees or optionees, in each case, determined at the time the expenses are incurred.  Penn shall provide prompt written notice to Sponsor of the existence of any such commercial licensee or optionee.  For the avoidance of doubt, in the event Sponsor does not exercise its option rights under Section 5.6 of this Agreement with respect to any Related Intellectual Property or Unrelated Intellectual Property during the applicable Option Period, or if the Parties are otherwise unable to execute an agreement pursuant to which Sponsor receives a license to any such Related Intellectual Property or Unrelated Intellectual Property during the applicable Negotiation Period, then Sponsor shall have no further obligation to reimburse Penn for any patent and legal expenses 

5

 

		
with respect to such Related Intellectual Property or Unrelated Intellectual Property following the expiration of such Option Period or Negotiation Period, as applicable.

	
5.4
	
Software.  Principal Investigator shall provide Penn and Sponsor a written disclosure of any copyrightable software created in the conduct of the Sponsored Research during the term of this Agreement that Principal Investigator reasonably considers to be scientifically valuable, provided that Principal Investigator shall have no obligation to provide the source code for such software.

	
5.5
	
Non-Exclusive Internal Research License.  Penn hereby grants to Sponsor a non-transferable (except as set forth in Section 9.7), non-exclusive license to use the Penn Intellectual Property for internal research purposes only for research of [***] in the Field of Use for a period beginning on the Effective Date and ending [***] following the expiration or earlier termination of this Agreement.

	
5.6
	
Options.

5.6.1Related Intellectual Property [***].  In consideration of Sponsor’s funding of the Sponsored Research and payment for intellectual property expenses as provided for in Section 5.3, Penn grants Sponsor a first exclusive option to negotiate to acquire a worldwide exclusive license, [***]with the right to sublicense through up to [***]tiers, on commercially reasonable terms, under the Related Intellectual Property, to make, have made, use, import, offer for sale and sell [***], in the Field of Use.  Any license to Related Intellectual Property for an invention that has not been reduced to practice in the conduct of the Sponsored Research is contingent upon execution of a subsequent sponsored research agreement with Sponsor for research to be conducted at Penn for reduction to practice of such invention.  Any license to [***]Products shall be limited to their use solely in conjunction with either or both of [***].  The Parties shall negotiate and incorporate into the License Agreement mutually agreeable and commercially reasonable financial terms and diligence milestones specific to the development of [***], or alternatively, negotiate and enter into a separate license agreement.  These diligence milestones shall take into account the stage of research and potential scientific challenges of the applicable [***] and reasonably expected timelines for achievement of such milestones.

If Sponsor fails to exercise its option to negotiate a license to any Related Intellectual Property prior to [***] after transmittal of the final report as set forth on Attachment A (the “Option Period”), or if Sponsor fails to make payment for intellectual property expenses as provided for in Section 5.3 with respect to such Related Intellectual Property, Penn shall be free to license such Related Intellectual Property to any party upon such terms as Penn deems appropriate, without any further obligation to Sponsor.  Sponsor shall notify Penn in writing within the Option Period if it intends to exercise such option (the “Option Exercise Notice”).  In the event Sponsor exercises such option, the Parties will negotiate appropriate financial and diligence terms in good faith for a period of [***] following the Option Exercise Notice (the “Negotiation Period”).  If the Parties come to agreement on such terms, then such terms shall be reflected in a license agreement executed by the Parties, or alternatively, (1) such patent application(s) or patent(s) in the Related Intellectual Property shall be included as appropriate in the License Agreement, (2) the financial and diligence terms of Exhibit B of the License Agreement shall be amended, and (3) as to each patent application that is Related Intellectual Property for which Sponsor has exercised its option, Sponsor shall amongst other consideration pay Penn an upfront fee to be negotiated by the Parties.  Prior to, and during the Option Period and Negotiation Period, Penn shall not assign, transfer, convey, or grant any rights in or otherwise encumber such 

6

 

Related Intellectual Property in any manner that would impair Sponsor’s rights in and to such Related Intellectual Property under this Agreement.

5.6.2[***]Unrelated Intellectual Property.  In further consideration of Sponsor’s funding of the Sponsored Research and payment for intellectual property expenses as provided for in Section 5.3, Penn grants Sponsor a first option during the Option Period to negotiate to acquire a non-exclusive worldwide license, with the right to sublicense through up to [***]tiers, on commercially reasonable terms, under the Unrelated Intellectual Property and [***], to make, have made, use, import, offer for sale and sell [***], in the Field of Use.  Any license to Unrelated Intellectual Property for an invention that has not been reduced to practice in the conduct of the Sponsored Research is contingent upon execution of a subsequent sponsored research agreement with Sponsor for research to be conducted at Penn for reduction to practice of such invention.  Notwithstanding the foregoing, [***] Information may only be sublicensed in combination with Penn Intellectual Property for manufacturing, development, or sale of a [***] in the Field of Use.  If Sponsor fails to exercise its option within the Option Period, or if Sponsor fails to make payment for intellectual property expenses as provided for in Section 5.3, Penn shall be free to license such Unrelated Intellectual Property to any party upon such terms as Penn deems appropriate, without any further obligation to Sponsor.  Sponsor shall provide Penn with an Option Exercise Notice within the Option Period if it intends to exercise such option.  In the event Sponsor exercises such option, the Parties will negotiate the terms of a license agreement with respect to such Unrelated Intellectual Property in good faith during the Negotiation Period.  Prior to, and during the Option Period and the Negotiation Period, Penn shall not assign, transfer, convey, or grant any rights in or otherwise encumber such Unrelated Intellectual Property in any manner that would impair Sponsor’s option to Unrelated Intellectual Property under this Agreement.

5.6.3Prospective Intellectual Property - [***].  Provided that (a) the Parties execute a prospective sponsored research agreement for research to be conducted at Penn in the field of [***] within [***] of the Effective Date, and (b) Sponsor agrees to provide payment for associated prospective Penn intellectual property expenses as they arise during the term of such future sponsored research agreement, Penn shall grant Sponsor an option to negotiate to acquire worldwide licenses, with the right to sublicense through up to [***]tiers, on commercially reasonable terms to Penn patent rights in the field of [***] controlled by Penn that are (x) conceived under the prospective sponsored research agreement, and (y) either (i) reduced to practice (as determined by United States patent law) under the prospective sponsored research agreement or (ii) disclosed to Penn’s Penn Center for Innovation on an invention disclosure form, to make, have made, use, import, offer for sale and sell [***] that use or incorporate targets selected from [***] to be developed under the prospective sponsored research program, within the Field of Use.  Any such license to Penn patent rights in the field of [***]based on an invention that has not been reduced to practice is contingent upon execution of a subsequent sponsored research agreement with Sponsor for research to be conducted at Penn for reduction to practice of such invention.  Any such license shall stipulate that [***] shall be used solely in conjunction with either of the [***]categories.  In the event that Penn receives an offer from a third party to support research in the Weissman laboratory for a [***] during the time period running for [***] after the Effective Date, Sponsor shall have a [***] first right of first refusal (“First Refusal Period”) to sponsor this [***]research, on an individual [***] basis.  Provided that a) Sponsor elects not to fund such Future CAAR Target during a First Refusal Period or b) the [***] period after the Effective Date expires, Penn may partner any [***] program not subject to a sponsored research agreement with Sponsor with any other party with no further obligations to Sponsor.

7

 

	
5.7
	
Retained Rights and Government Rights.  Any license granted to Sponsor pursuant to Section 5.5 and 5.6 hereof shall be subject to Penn’s right to use and permit other nonprofit organizations to use Penn Intellectual Property for educational, research and patient care purposes, and if applicable, to the rights of the United States government reserved under Public Laws 96-517, 97-256 and 98-620, codified at 35 U.S.C. 200-212, and any regulations issued thereunder.  Notwithstanding the foregoing, any license granted to Sponsor pursuant to Section 5.5 or 5.6 shall not include retained rights that extend to Penn’s patient care purposes by the Weissman laboratory for any Product during the time period when such Product is in active clinical development by Sponsor and ending upon marketing approval of such Product, to the extent Sponsor has provided details of such Product to Penn in writing prior to IND filing for such Product.

Article 6
CONFIDENTIALITY & PUBLICATION

	
6.1
	
Confidential Information.  Sponsor does not intend to disclose confidential information to Penn unless it is necessary to or useful for the performance of the Sponsored Research.  Notwithstanding the foregoing, Sponsor may provide Penn with scientific, technical, business, or other information which is treated by Sponsor as confidential or proprietary (“Confidential Information”).  Any Confidential Information provided by Sponsor will be in writing and clearly marked by Sponsor as “Confidential” or, if disclosed orally, written notice of the confidential nature thereof will be provided within [***] of disclosure.  Penn shall protect Sponsor’s Confidential Information with the same degree of care as Penn’s own confidential information.  Penn shall not use Confidential Information for any purpose other than in connection with performing the Sponsored Research, and shall not disclose Confidential Information to any third party without Sponsor’s prior written consent.  The Confidential Information provided to Penn by Sponsor will remain the property of the Sponsor, and will be disclosed by Penn only to those persons necessary for the performance of this Agreement who are under obligations of confidentiality substantially similar to those contained herein.  Penn’s and the Principal Investigator’s obligations of confidentiality will exist during the performance of this Agreement and for [***] following termination or expiration of this Agreement, unless disclosure is required by law or regulation.

The confidentiality obligations contained herein shall not apply to Confidential Information that is:

	
 
	
i.
	
Known by Penn or Principal Investigator without restriction prior to disclosure under this Agreement;

	
 
	
ii.
	
Disclosed to Penn or Principal Investigator by a third party without an obligation of confidentiality;

	
 
	
iii.
	
Available to the public not through a breach of this Agreement by Penn or Principal Investigator;

	
 
	
iv.
	
Independently developed by Penn or Principal Investigator without knowledge or use of, or reference to, Confidential Information disclosed by Sponsor under this Agreement as evidenced by Penn’s written records; or

	
 
	
v.
	
Published or disclosed in accordance with the terms of this Agreement.

	
6.2
	
Disclosure Required by Court Order or Law.  If Penn is required to disclose Confidential Information, or any terms of the Agreement, pursuant to the valid order or requirement of a court, administrative agency, or other governmental body or applicable law, Penn may disclose such 

8

 

		
Confidential Information or terms to the extent required, provided, however, that Penn promptly provides to the Sponsor with prior written notice (to the extent legally permissible) of such disclosure and Sponsor may attempt to obtain an order or other remedy protecting the Confidential Information from public disclosure.  To the extent that Confidential Information so disclosed does not become part of the public domain by virtue of such disclosure, it shall remain Confidential Information protected pursuant to Section 6.1.

	
6.3
	
Penn Intellectual Property.  In order to preserve the patentability of Penn Intellectual Property and to preserve Penn’s publication rights, Sponsor shall maintain Penn Intellectual Property, Research Results and information provided pursuant to the Sponsored Research (whether oral or written) as confidential and shall not disclose such information to any third party until the publication of such information by the Principal Investigator or until Penn provides Sponsor with written verification that all desirable patentable inventions have been protected, whichever occurs sooner, provided, however, that Sponsor may disclose such information to actual or potential investors, acquirers, partners, collaborators, licensees, or sub-licensees without Penn’s prior written consent, provided such third parties are subject to written confidentiality obligations substantially similar to those contained herein.  Sponsor’s obligations of confidentiality will exist during the term of this Agreement and for [***] following the termination or expiration of this Agreement, unless disclosure is required by law or regulation.

Sponsor shall have the right to disclose any of the information described above to the extent required pursuant to the valid order or requirement of a court, administrative agency, or other governmental body or applicable law, subject to the terms and obligations set forth in Section 6.2, mutatis mutandis.  The confidentiality obligations contained in this Section 6.3 shall not apply to any information that is subject to any of the clauses (i) through (v) of Section 6.1, mutatis mutandis.

Penn shall maintain Penn Intellectual Property and Research Results as confidential and shall not disclose such information to any third party until the publication or presentation of such information by the Principal Investigator pursuant to the terms of this Agreement, provided, however, that (a) Research Results and Penn Intellectual Property shall not be considered Confidential Information for purposes of publication in accordance with Section 6.4 below, (b) Penn shall be permitted to disclose Penn Intellectual Property and Research Results in patent applications and related documents, (c) Penn may disclose Penn Intellectual Property in the event Sponsor does not exercise its option to such Penn Intellectual Property under Section 5.5 above or a license agreement, including the License Agreement, is not entered into with respect to such Penn Intellectual Property, and (d) Penn may use and disclose Research Results for educational and noncommercial research purposes.  Penn’s obligations of confidentiality under this paragraph will exist during the term of this Agreement and for the earlier of (i) [***] following the termination or expiration of this Agreement or (ii) the publication or presentation of such Research Results, unless disclosure is required by law or regulation.

	
6.4
	
Publications.  Penn shall have the first right to publish or present Research Results or other information and material resulting from the Sponsored Research.  Penn shall furnish the Sponsor with a copy of any proposed publication or presentation at least [***] in advance of the date of such presentation or the submission of said proposed publication in order for Sponsor to review and comment on said proposed publication or presentation to (a) determine whether such contains any Confidential Information and (b) enable Sponsor to identity any Penn Intellectual Property that it wishes Penn to file patent applications on or to seek other intellectual property protection for.  If within the [***]review period (i) Sponsor notifies Penn that the Sponsor requires deletion from the publication or presentation of Sponsor Confidential Information, the Parties will cooperate to modify the disclosure to ensure Sponsor Confidential Information is not disclosed or (ii) if Sponsor 

9

 

		
requests that publication or presentation be delayed to allow for patent filings or other intellectual property protection on certain items in the proposed publication or presentation, Penn shall delay the publication or presentation for up to [***] to allow for the filing of patent applications or other intellectual property protection.

Article 7
TERM & TERMINATION

	
7.1
	
Term.  The initial term of this Agreement shall begin on the Effective Date of this Agreement and shall end on the [***] of the Effective Date unless terminated sooner pursuant to Sections 2.2 or 7.2 hereof (the “Term”).  This Agreement may be extended or renewed only by mutual written agreement executed by duly authorized representatives of the Parties.

	
7.2
	
Termination.  In addition to the termination right set forth in Section 2.2 hereof,

	
 
	
i.
	
either Party may terminate this Agreement effective upon written notice to the other Party, if the other Party breaches any of the terms or conditions of this Agreement and fails to cure such breach within [***] after receiving written notice thereof.  In the event of an incurable breach, the non-breaching Party may terminate this Agreement effective immediately upon written notice to the breaching Party; or

	
 
	
ii.
	
Sponsor may terminate this Agreement in its entirety, or on an [***], for any or no reason effective upon [***] written notice to Penn.  For clarity, cessation or truncation of a sub-project pertaining to an individual [***] shall not be deemed termination of the Agreement.

	
7.3
	
Effects of Termination.

	
 
	
i.
	
Any early termination of the Agreement shall result in automatic cross-termination of the Background IP Option Agreement with immediate effect.  For clarity, any termination of this Agreement following Sponsor’s full payment to Penn of the initially agreed-upon budget of [***] shall not be considered early termination of the Agreement for purposes of this Section 7.3(i).

	
 
	
ii.
	
In the event of termination of this Agreement prior to its stated term whether for breach or for any other reason whatsoever, Penn shall be entitled to payment for the work in progress up to the date of termination, and for allowable costs, to the extent contemplated in the budget included in Attachment A.  Allowable costs include, without limitation, [***].  In the event of termination, or upon expiration of this Agreement, Penn shall submit a final report of all costs incurred and all funds received under this Agreement within [***] after the effective termination or expiration date.  The report shall be accompanied by a check in the amount of any excess of funds advanced over costs and allowable commitments incurred.  In case of a deficit of funds, Sponsor shall pay Penn the amount needed to cover costs and allowable commitments incurred by Penn under this Agreement (for clarity, to the extent such costs and commitments are included in the budget).

	
 
	
iii.
	
Termination or expiration of this Agreement shall not affect the rights and obligations of the Parties accrued prior to termination hereof.  The provisions of ARTICLE 3; ARTICLE 4; ARTICLE 5; ARTICLE 6; ARTICLE 7; ARTICLE 8; and ARTICLE 9, shall survive such termination or expiration.

10

 

Article 8
DISCLAIMER OF WARRANTIES, INDEMNIFICATION

	
8.1
	
PENN MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, WARRANTIES WITH RESPECT TO THE CONDUCT, COMPLETION, SUCCESS OR PARTICULAR RESULTS OF THE SPONSORED RESEARCH, OR THE CONDITION, OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE SPONSORED RESEARCH OR ANY PENN INTELLECTUAL PROPERTY OR RESEARCH RESULTS OR THAT USE OF PENN INTELLECTUAL PROPERTY OR RESEARCH RESULTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT OF A THIRD PARTY.  EXCEPT IN THE CASE OF PENN’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, PENN SHALL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, PUNITIVE OR OTHER DAMAGES SUFFERED BY SPONSOR OR ANY OTHER PERSON RESULTING FROM THE SPONSORED RESEARCH OR SPONSOR’S USE OF ANY PENN INTELLECTUAL PROPERTY, ANY RESEARCH RESULTS OR ANY PRODUCTS RESULTING THEREFROM.  EXCEPT IN THE CASE OF SPONSOR’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, SPONSOR SHALL NOT BE LIABLE FOR ANY INDIRECT.  CONSEQUENTIAL OR PUNITIVE DAMAGES SUFFERED BY PENN RESULTING FROM THE SPONSORED RESEARCH OR PENN’S USE OF ANY PENN INTELLECTUAL PROPERTY, ANY RESEARCH RESULTS OR ANY PRODUCTS RESULTING THEREFROM; PROVIDED, THAT, FOR THE AVOIDANCE OF DOUBT, THIS SECTION 8.1 SHALL NOT BE INTERPRETED TO AFFECT OR LIMIT SPONSOR’S INDEMNIFICATION OBLIGATION UNDER SECTION 8.2 BELOW.

	
8.2
	
Indemnification.

Sponsor shall indemnify, defend and hold harmless Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the “Penn Indemnitees”) from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees), which the Penn Indemnitees may hereafter incur, or be required to pay as a result of Sponsor’s use of any Penn Intellectual Property or Research Results or as a result of any breach of this Agreement or any act or omission of Sponsor, its employees, affiliates, contractors, licensees or agents, provided that Sponsor’s obligations pursuant to this Section 8.2 shall not apply to the extent such claims or suits result from the negligence or willful misconduct of any of Penn Indemnitees or any breach of this Agreement by Penn, each as determined by a court of law.

As a condition to a Penn Indemnitee’s right to receive indemnification under this Section 8.2, Penn shall:  (a) promptly notify Sponsor when it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) cooperate with Sponsor in the defense, settlement or compromise of such claim or suit; and (c) permit the Sponsor to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel.  In no event, however, may Sponsor compromise or settle any claim or suit in a manner which (a) admits fault or negligence on the part of Penn or any other Penn Indemnitee; or (b) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn.  Penn shall reasonably cooperate with Sponsor and its counsel in the course of the defense of any such suit, claim or demand.

11

 

Article 9
ADDITIONAL PROVISIONS

	
9.1
	
Force Majeure.  Neither Party shall be liable for any failure to perform as required by this Agreement to the extent such failure to perform is due to circumstances reasonably beyond such Party’s control, including, without limitation, labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval required for full performance, civil disorders or commotions, terrorism, acts of aggression, acts of God, unforeseeable and irresistible energy or other conservation measures imposed by law or regulations, explosions, failure of utilities, material shortages, disease, or other such occurrences.

	
9.2
	
Relationship of the Parties.  Nothing in this Agreement is intended or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties.  The Parties are independent contractors and at no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.

	
9.3
	
Expenses.  Except as otherwise provided in this Agreement, each Party shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby

	
9.4
	
Third Party Beneficiary.  No party, other than Penn or Sponsor shall be entitled to any rights whatsoever by virtue of the relationships created by or arising under this Agreement, including, without limitation, rights as a third party beneficiary

	
9.5
	
Use of Names.  Except as set forth in the License Agreement, Sponsor and its affiliates may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without the prior written consent of Penn.  Notwithstanding the foregoing, Sponsor may use the name of Penn and the Principal Investigator and other Penn employees directly supported by Sponsored Research funds as identified in the budget set forth in Attachment A in a non-misleading and factual manner solely to state Sponsor’s funding of this Sponsored Research.  Except as set forth in the License Agreement, Penn shall not use Sponsor’s name without Sponsor’s prior written consent except that Penn may acknowledge Sponsor’s funding of this Sponsored Research and any scientific contributions in scientific publications, in listings of sponsored research projects and for other academic purposes.

	
9.6
	
No Discrimination.  Neither Penn nor Sponsor will discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status.

	
9.7
	
Successors and Assignment.

The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns.

Sponsor may not assign or transfer this Agreement or any of Sponsor’s rights or obligations created hereunder, by operation of law or otherwise, without the prior written consent of Penn.  Notwithstanding the foregoing, Sponsor may assign its rights and obligations under this Agreement without the prior written consent of Penn to a successor in connection with the merger, consolidation, reorganization or sale of all or substantially all of its assets or its business; provided, 

12

 

that (I) there exists no material breach by Sponsor of any material term of this Agreement, (II) Sponsor provides prompt written notice of the transaction to Penn, and (III) the assignee agrees in writing to be legally bound by this Agreement.  Any permitted assignment will not relieve Sponsor of any obligation of Sponsor that has accrued at the time of the assignment.

Any assignment not in accordance with this Section 9.7 shall be void.

	
9.8
	
Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

	
9.9
	
Entire Agreement of the Parties; Amendments.  This Agreement and the Schedules and Attachments hereto, the Background IP Option Agreement, constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter.  No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.

	
9.10
	
Governing Law.  This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.

	
9.11
	
Dispute Resolution.  If a dispute arises between the Parties concerning this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute.  If the Parties are unable to resolve such dispute amicably, then the Parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania.

	
9.12
	
Notices and Deliveries.  Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and directed to a Party at its address shown below or such other address as such Party shall have last given by notice to the other Party.  A notice will be deemed received:  if delivered personally, on the date of delivery; if mailed, [***] after deposit in the United States mail; if sent via courier, [***] after deposit with the courier service.

		
	
For Penn
	
with a copy to:

	
[***]
	
[***]

	
For Sponsor:
	
with a copy to:

	
[***]
	
[***]

 

	
9.13
	
Waiver.  A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof.  All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.

13

 

	
9.14
	
Severability.  When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.  The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.

	
9.15
	
Interpretation.  The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Articles, Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall otherwise require.

	
9.16
	
Counterparts.  This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument.  A portable document format (PDF) or electronic copy of this Agreement, including the signature pages, will be deemed an original.

[SIGNATURE PAGE FOLLOWS]

 

 

14

 

 

IN WITNESS WHEREOF, the duly authorized representatives of the Parties hereby execute this Agreement as of the date first written above.

 

	
THE TRUSTEES OF THE
	
 
	
 

	
UNIVERSITY OF PENNSYLVANIA
	
 
	
 
	
 
	
CABALETTA BIO, INC

	
By:
	
[***]
	
 
	
 
	
By:
	
 
	
/s/ Steven Nichtberger

	
Name:
	
[***]
	
 
	
 
	
Name:
	
 
	
Steven Nichtberger

	
Title:
	
[***]
	
 
	
 
	
Title:
	
 
	
Chief Executive Officer

 

 

 

I have read and understood the responsibilities
of the Principal Investigator:

 

	
Signature:
	
/s/ Drew Weissman

	
 
	
Dr. Drew Weissman

 

 

[Signature Page to Sponsored Research Agreements]

 

 

 

Attachment A

Summary of Sponsored Research

Work Scope & Details of Program — See attached Appendix 1 to Attachment A.

Principal Investigator - Drew Weissman, M.D., Ph.D.; [***]

Representative of Sponsor - Steven Nichtberger; [***]

Period of Performance — [***]

Report Schedule — Final report due within [***] after completion of the Sponsored Research.

Interim reports due [***] after commencement of the Sponsored Research.

Budget— See attached Appendix 2 to Attachment A; [***].

Payments under this Agreement will be payable within [***] of Sponsor’s receipt of an invoice from Penn.

Payment Schedule —

		
	
Date Payment Due
	
Amount of Payment Due

	
[***]
	
[***]

	
[***]
	
[***]

 

 

 

 

 

 

APPENDIX 1 TO ATTACHMENT A

WORK SCOPE & DETAILS OF PROGRAM

[***]

 

 

 

APPENDIX 2 TO ATTACHMENT A

BUDGET

[***]

									
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 

	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

 

 

 

2caba-ex1030_56.htm

 

Exhibit 10.30

 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

University of Pennsylvania

Option Agreement

Signature Page

		
	
Company Information

	
Company’s full legal name and address:

Cabaletta Bio, Inc.

2929 Arch Street, Suite 600

Philadelphia, PA 19104
	
Company primary phone number:

267-759-3100

	
Company primary fax number:

 

			
	
Penn Information

	
Notice Address:
	
Payment Address:
	
 

	
[***]
	
By ACH/Wire:

[***]
	
By Check (lockbox):

[***]

 

1

Final Execution Copy

 

 

 

		
	
Patent Rights

	
Penn Dockets and Descriptions:

See Attachment A
	
Field of Use:

“Field of Use’ means the following subfields (each a “Subfield”): [***].

	
Licensed Product:

“Licensed Product” means [***]

 

	
	
Payment Terms

	
Option Fee: $[***]

 

		
	
Term

	
Effective Date: The effective date of SRA (as defined in Section 2)
	
Initial Term: Until [***].

 

		
	
Signatures

	
This Agreement includes this Signature Page and all of the attached Terms and Conditions. By signing below, Company and Penn agree to all of the provisions.

	
Cabaletta Bio, Inc.
	
The Trustees of the University of Pennsylvania

	
By: /s/ Steven NichtbergerDate: December 23, 2021

(please sign)

Name: Steven Nichtberger, MD

Title: CEO
	
By: [***] Date: December 23, 2021

(please sign)

Name: [***]Title: [***]

 

 

 

2

Final Execution Copy

 

 

 

Option Agreement

Terms and Conditions

 

 

1.Option Grant. Penn grants to Company a first option, during the Term, to negotiate to acquire a non-exclusive worldwide license, with the right to sublicense through up to [***]tiers, to make, have made, use, import, offer for sale and sell Licensed Products using or incorporating Patent Rights in the Field of Use (the “Option”). The term “Patent Rights’ means (a) all of Penn’s patent rights represented by or issuing from the Penn dockets listed on the Signature Page, (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals, divisional and re-issue applications thereof, but excluding continuations-in-part except to the extent of claims entirely supported in the specification and entitled to the priority date of the parent application, and (c) any corresponding foreign counterparts and any extensions to the foregoing. No other rights and no licenses are granted.

2.License Negotiations. During the Term, but only following execution of the SRA, Company shall notify Penn in writing if it intends to exercise the option set forth in Section 1 above. In the event Company exercises such option, Company and Penn will negotiate in good faith the terms and conditions of a definitive Patent License Agreement for the Patent Rights for a period of [***]and [***] thereafter (the “Negotiation Period”). During [***], Penn will not enter into any negotiations with any third party regarding an exclusive commercial license under the Patent Rights for use with or incorporation into Licensed Products in the Field of Use that would conflict with the option rights granted to Company hereunder. “SRA” means a sponsored research agreement between Company and Penn for mRNA-LNP research involving CAARs to be conducted in the Weissman Lab at Penn and executed by the parties concurrently with this Agreement. Under the SRA, Company shall provide committed funding to Penn’s Weissman Lab of at least $[***] for development of products and services related to the Patent Rights in the Field of Use.

3.Minimum Terms. Any Patent License Agreement negotiated pursuant to this Agreement will be based upon Penn’s standard Patent License Agreement, or if deemed applicable by the parties, the Cabaletta Amended and Restated License Agreement dated effective July 23, 2019 by and among Penn, CHOP, and Company, as amended by its First Amendment dated May 1, 2020 and its Second Amendment dated October 19, 2021. Any license will be subject to any applicable rights retained by the US government in intellectual property funded by a Federal agency. In any license, Penn will reserve the right to use, and to allow other non-commercial entities to use, the Patent Rights for educational, research and patient care purposes.

4.Option Fee. On the Effective Date, Company will pay to Penn the non-refundable and non-creditable Option Fee.

3

Final Execution Copy

 

 

5.Expiration. This Agreement will expire automatically at the end of the Term unless otherwise agreed upon by both parties in writing.

6.Early Termination. This Agreement will terminate before the expiration of the Term: (a) upon the written agreement of both parties to such termination, or (b) upon [***] prior written notice by Company of its intention to terminate at any time, or (c) immediately upon early termination of the associated SRA.

7.Effect of Expiration or Termination. Upon the expiration or termination of this Agreement for any reason (except for termination upon execution of a definitive Patent License Agreement, and only following the Negotiation Period if applicable): Penn may exclusively license the Patent Rights in the Field of Use to any third party at any time and upon any terms without further obligation to Company. The terms and conditions of Paragraphs 7, 11, 12, 13 and 14 will survive in accordance with their respective terms. If Company has exercised its option during the Term, then Company’s rights to negotiate a license as set forth in Section 2 shall survive such expiration for the time period set forth in such Section 2.

8.Intentionally Omitted

9.Payment Terms. All payments are payable to “The Trustees of the University of Pennsylvania” at the payment addresses shown on the Signature Page. All payments will be in United States Dollars.

10.Patent Maintenance. Except as may otherwise be agreed by the parties, in a definitive Patent License Agreement or otherwise, Penn will control, prosecute and maintain the Patent Rights during the Term. During the Term, Penn will, use reasonable efforts to inform Company, through its patent counsel, material patent prosecution decisions that are pending related to the Patent Rights, and will reasonably consider Company’s input on such decisions.

11.Patent Expenses. Company will reimburse Penn for all patent and legal expenses incurred by Penn during the Term with respect to the Patent Rights at the rate of (a) [***] of the expenses if there are no other active commercial licensees or optionees, and (b) [***] with other active commercial licensees or optionees, in each case determined at the time the expenses are incurred. Penn shall promptly inform Company of the number of any such active commercial licensees or optionees. If Company does not reimburse any such expenses then Penn may proceed with such patent action at its own cost and expense and any patent rights associated with such patent action will be automatically excluded from the term “Patent Rights”‘ and Company’s option under Paragraph 1.

12.Penn’s Name. Company will not use Penn’s name or trademarks or the name of any Penn employee in any manner without Penn’s prior written consent. Notwithstanding the foregoing, Company may use the name of Penn in a non-misleading and factual manner solely to state that Company has entered into this Option Agreement and been granted the Option. Penn will not use Company’s name or trademarks without the prior written consent of Company except that Penn may use the name of Company in a non-misleading and factual manner solely to state that Penn has entered into this Option Agreement and granted the Option to Company.

4

Final Execution Copy

 

 

13.Disclaimer. PENN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE.

14.Miscellaneous. Any notice must be in writing and sent to the address of the party listed on the Signature Page. This Agreement may only be modified by a written amendment that is executed by an authorized representative of each party. Any waiver must be express and in writing. No waiver by either party of a breach by the other party will constitute a waiver of any different or succeeding breach. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania without regard to conflicts of law principles of any jurisdiction. The parties will use reasonable efforts to resolve amicably any disputes that may relate to or arise under this Agreement. If the parties are unable to resolve the dispute amicably, then the parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania. This Agreement, together with the SRA and any Confidential Disclosure Agreement contain the entire agreement between the parties with respect to subject matter of this Agreement and supersede all other oral or written representations, statements, or agreements with respect to such subject matter. This Agreement is binding upon the parties and their respective heirs, successors, assigns, and personal representatives. Neither party may assign this Agreement without the prior written consent of the other party.

Notwithstanding the foregoing, Company may assign its rights and obligations under this Option Agreement without the prior written consent of Penn to a successor in connection with the merger, consolidation or sale of all or substantially all of its assets or its business, provided, that (i) there exists no material breach by Company of any material term of this Option Agreement, (ii) Company provides prompt written notice of the transaction to Penn, and (iii) the assignee agrees in writing to be legally bound by this Agreement. Any permitted assignment will not relieve Company of any obligation of Company that has accrued at the time of the assignment.

 

 

 

5

Final Execution Copy

 

 

 

Attachment A

Patents and Patent Applications in Penn Patent Rights

[***]

 

 

 

 

6

Final Execution Copy

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]